Literature DB >> 27111245

Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation.

Wenwen Zhang1, Lulu Cao1, Zijia Sun1, Jing Xu1, Lin Tang1, Weiwei Chen1, Jiayan Luo1, Fang Yang1, Yucai Wang2, Xiaoxiang Guan1,3.   

Abstract

The F box protein Skp2 is oncogenic. Skp2 and Skp2B, an isoform of Skp2 are overexpressed in breast cancer. However, little is known regarding the mechanism by which Skp2B promotes the occurrence and development of breast cancer. Here, we determined the expression and clinical outcomes of Skp2 in breast cancer samples and cell lines using breast cancer database, and investigated the role of Skp2 and Skp2B in breast cancer cell growth, apoptosis and cell cycle arrest. We obtained Skp2 is significantly overexpressed in breast cancer samples and cell lines, and high Skp2 expression positively correlated with poor prognosis of breast cancer. Both Skp2 and Skp2B could promote breast cancer cell proliferation, inhibit cell apoptosis, change the cell cycle distribution and induce the increased S phase cells and therefore induce cell proliferation in breast cancer cells. Moreover, the 2 isoforms could both suppress PIG3 expression via independent pathways in the breast cancer cells. Skp2 suppressed p53 and inhibited PIG3-induced apoptosis, while Skp2B attenuated the function of PIG3 by inhibiting PHB. Our results indicate that Skp2 and Skp2B induce breast cancer cell development and progression, making Skp2 and Skp2B potential molecular targets for breast cancer therapy.

Entities:  

Keywords:  PHB; PIG3; Skp2; Skp2B; breast cancer; p53; prognosis; proliferation

Mesh:

Substances:

Year:  2016        PMID: 27111245      PMCID: PMC4889242          DOI: 10.1080/15384101.2016.1160986

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  40 in total

1.  Skp2 is required for Aurora B activation in cell mitosis and spindle checkpoint.

Authors:  Juan Wu; Yu-Fan Huang; Xin-Ke Zhou; Wei Zhang; Yi-Fan Lian; Xiao-Bin Lv; Xiu-Rong Gao; Hui-Kuan Lin; Yi-Xin Zeng; Jian-Qing Huang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.

Authors:  Bing Hao; Ning Zheng; Brenda A Schulman; Geng Wu; Julie J Miller; Michele Pagano; Nikola P Pavletich
Journal:  Mol Cell       Date:  2005-10-07       Impact factor: 17.970

3.  A model for p53-induced apoptosis.

Authors:  K Polyak; Y Xia; J L Zweier; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1997-09-18       Impact factor: 49.962

4.  Damage-induced BRCA1 phosphorylation by Chk2 contributes to the timing of end resection.

Authors:  Balaji Parameswaran; Huai-Chin Chiang; Yunzhe Lu; Julia Coates; Chu-Xia Deng; Richard Baer; Hui-Kuan Lin; Rong Li; Tanya T Paull; Yanfen Hu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.

Authors:  Azfar Jamal; Manickavinayaham Swarnalatha; Sarwat Sultana; Prashant Joshi; Subrat K Panda; Vijay Kumar
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Skp2 is oncogenic and overexpressed in human cancers.

Authors:  M Gstaiger; R Jordan; M Lim; C Catzavelos; J Mestan; J Slingerland; W Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

7.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication.

Authors:  K Nakayama; H Nagahama; Y A Minamishima; M Matsumoto; I Nakamichi; K Kitagawa; M Shirane; R Tsunematsu; T Tsukiyama; N Ishida; M Kitagawa; K Nakayama; S Hatakeyama
Journal:  EMBO J       Date:  2000-05-02       Impact factor: 11.598

8.  Skp2 suppresses p53-dependent apoptosis by inhibiting p300.

Authors:  Mayumi Kitagawa; Sang Hyun Lee; Frank McCormick
Journal:  Mol Cell       Date:  2008-02-01       Impact factor: 17.970

9.  GOBO: gene expression-based outcome for breast cancer online.

Authors:  Markus Ringnér; Erik Fredlund; Jari Häkkinen; Åke Borg; Johan Staaf
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner.

Authors:  Wenwen Zhang; Jiayan Luo; Fengxia Chen; Fang Yang; Wei Song; Aiyu Zhu; Xiaoxiang Guan
Journal:  Oncotarget       Date:  2015-04-10
View more
  18 in total

1.  Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis.

Authors:  He Shen; Nuo Yang; Alexander Truskinovsky; Yanmin Chen; Ashley L Mussell; Norma J Nowak; Lester Kobzik; Costa Frangou; Jianmin Zhang
Journal:  Mol Cancer Res       Date:  2018-09-20       Impact factor: 5.852

2.  Prohibitin promotes androgen receptor activation in ER-positive breast cancer.

Authors:  Pengying Liu; Yumei Xu; Wenwen Zhang; Yan Li; Lin Tang; Weiwei Chen; Jing Xu; Qian Sun; Xiaoxiang Guan
Journal:  Cell Cycle       Date:  2017-03-08       Impact factor: 4.534

3.  SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells metastasis by sponging miR-942-5p and activating PI3K/Akt signaling.

Authors:  Wenwen Zhang; Shuofei Yang; Datian Chen; Daolu Yuwen; Juan Zhang; Xiaowei Wei; Xin Han; Xiaoxiang Guan
Journal:  Cell Mol Life Sci       Date:  2022-01-07       Impact factor: 9.261

Review 4.  Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism.

Authors:  J Wei; Z Liu; J He; Q Liu; Y Lu; S He; B Yuan; J Zhang; Y Ding
Journal:  Clin Transl Oncol       Date:  2021-10-13       Impact factor: 3.405

Review 5.  Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.

Authors:  Pranav Gupta; Hongling Zhao; Bang Hoang; Edward L Schwartz
Journal:  Br J Cancer       Date:  2022-06-25       Impact factor: 9.075

6.  Genistein inhibits the S-phase kinase-associated protein 2 expression in breast cancer cells.

Authors:  Dengfeng Ye; Zhian Li; Chunshou Wei
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

7.  Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells.

Authors:  Xuyuan Yin; Yu Zhang; Jingna Su; Yingying Hou; Lixia Wang; Xiantao Ye; Zhe Zhao; Xiuxia Zhou; Yali Li; Zhiwei Wang
Journal:  Oncotarget       Date:  2016-10-11

Review 8.  Emerging Roles of SKP2 in Cancer Drug Resistance.

Authors:  Ting Wu; Xinsheng Gu; Hongmei Cui
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

9.  Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer.

Authors:  DeokBeom Jung; Ashwani Khurana; Debarshi Roy; Eleftheria Kalogera; Jamie Bakkum-Gamez; Jeremy Chien; Viji Shridhar
Journal:  Sci Rep       Date:  2018-02-06       Impact factor: 4.379

10.  Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathway.

Authors:  Yu-Shih Lin; Yin-Yin Lin; Yao-Hsu Yang; Chun-Liang Lin; Feng-Che Kuan; Cheng-Nan Lu; Geng-He Chang; Ming-Shao Tsai; Cheng-Ming Hsu; Reming-Albert Yeh; Pei-Rung Yang; I-Yun Lee; Li-Hsin Shu; Yu-Ching Cheng; Hung-Te Liu; Kuan-Der Lee; De-Ching Chang; Ching-Yuan Wu
Journal:  BMC Complement Altern Med       Date:  2018-05-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.